Pharmacogenomics holds the promise that drugs might one day be tailored to your genetic makeup.By Mayo Clinic Staff
Modern medications save millions of lives a year. Yet any one medication might not work for you, even if it works for other people. Or it might cause severe side effects for you but not for someone else.
Your age, lifestyle and health all influence your response to medications. But so do your genes. Pharmacogenomics is the study of how a person's unique genetic makeup (genome) influences his or her response to medications.
Pharmacogenomics is part of a field called personalized medicine — also called individualized or precision medicine — that aims to customize health care, with decisions and treatments tailored to each individual patient in every way possible.
Although genomic testing is still a relatively new development in drug treatment, this field is expanding. Currently, more than 100 drugs have label information regarding pharmacogenomic biomarkers — some measurable or identifiable segment of genetic information that can be used to direct the use of a drug.
Each gene provides the blueprint for the production of a certain protein in the body. A particular protein may have an important role in drug treatment for one of several reasons, including the following:
- The protein plays a role in breaking down the drug.
- It helps with the absorption or transport of the drug.
- The protein is the actual target of the drug.
- It has some role in a series of molecular events triggered by the drug.
When researchers compare the genomes of people taking the same drug, they may discover that a set of people who share a certain genetic variation also share a common treatment response, such as:
- A greater risk of side effects
- Severe side effects at relatively low doses
- The need for a higher dose to achieve a therapeutic effect
- No benefit from the treatment
- A greater or more likely benefit from the treatment
- The optimal duration of treatment
This kind of treatment information is currently used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.
In cancer treatments, there are two genomes that may influence prescribing decisions — the genome of the person with cancer and the genome of the cancerous (malignant) tumor.
There are many causes of cancer, but most cancers are associated with damaged DNA that allows cells to grow unchecked. The "incorrect" genetic material of the unchecked growth — the malignant tumor — is really a separate genome that may provide clues for treatment. For example, the drug trastuzumab (Herceptin) is most likely to be effective against breast cancer cells that have an extra copy of a particular gene and high levels of the gene's corresponding protein.
An example of pharmacogenomics in treatment decisions is the use of a blood-thinning drug called warfarin (Coumadin, Jantoven). If you have a blood clot, your treatment may include a prescription for warfarin to treat the current clot and to prevent additional blood clots from forming.
Your doctor's goal is to prescribe a dose that will be strong enough to prevent blood clotting but not strong enough to cause adverse reactions, such as internal bleeding (hemorrhaging). The window for the effective and safe dose of this drug for any person is relatively narrow.
Dosage has traditionally been based on such factors as weight, age, and kidney and liver function, as well as a laboratory test to assess the blood-thinning effect of the drug in each person. The dosing guidelines, although valuable, may have limited value in predicting the outcome for every person.
In the early 2000s, studies comparing treatment outcomes with genomic data revealed that genetic variation was associated with either an increased risk of hemorrhaging or with the need for a higher dose to be effective.
Because of these findings, your doctor may use your genomic information to help guide treatment decisions. A tissue sample swabbed from inside your cheek or a blood sample provides cells for a laboratory test to decipher your genome.
Based on the results, your doctor may judge more accurately what dose of warfarin is likely to be safe and effective for you or whether warfarin is even an appropriate treatment option.
Although pharmacogenomics has much promise and has made important strides in recent years, it's still in its early stages. Clinical trials are needed not only to identify links between genes and treatment outcomes but also to confirm initial findings, clarify the meaning of these associations and translate them into prescribing guidelines.
Nonetheless, progress in this field points toward a time when pharmacogenomics may be part of routine medical care.
June 05, 2015
- Personalized medicine. U.S. Food and Drug Administration. http://www.fda.gov/ScienceResearch/SpecialTopics/PersonalizedMedicine/default.htm. Accessed April 30, 2015.
- Godman B, et al. Personalizing health care: Feasibility and future implications. BMC Medicine. 2013;11:179.
- Tremblay J, et al. Role of genomics on the path to personalized medicine. Metabolism. 2013;62(suppl):S2.
- Wang L, et al. Genomics and drug response. New England Journal of Medicine. 2011;364:1144.
- Table of pharmacogenomic biomarkers in drug labeling. U.S. Food and Drug Administration. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed April 30, 2015.
- Frequenty asked questions about pharmacogenomics. National Human Genome Research Institute. http://www.genome.gov/27530645. Accessed May 1, 2015.
- Frequently asked questions about pharmacogenomics. National Institute of General Medical Sciences. http://www.nigms.nih.gov/rss/WhatsNewXML/Pages/pgrn_faq.aspx. Accessed April 30, 2015.